Naslov
Tumor Mass Assessment in CLL. Distinction between sCD23 and etab-2 Microglobulin
(Tumor Mass Assessment in CLL. Distinction between sCD23 and beta-2 Microglobulin)

Autori
Jakšić, Ozren ; Kušec, Rajko ; Kardum, Mirjana Mariana ; Kušec, Vesna ; Jakšić, Branimir

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the ASH 40th Annual Meeting ; u: Blood. Supplement / - , 1998, A4146-a4146

Skup
ASH Annual Meeting (40 ; 1998)

Mjesto i datum
Miami (FL), Sjedinjene Američke Države, 04.12.1998. - 08.12.1998

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
CLL; tumor distribution; sCD23; beta-2 microglobulin

Sažetak
Reliable assessment of tumor mass in CLL is necessary for monitoring of disease progression and to evaluate the effect of therapy. Recently, both soluble CD23 (sCD23) and beta-2 microglobulin (B2MG) have been reported to correlate with the extent of the disease, but mutual relationship between these two markers have not been extensively studied. Therefore, we performed uni- and multivariate analyses to evaluate biochemical markers including sCD23, beta-2 microglobulin and LDH in 76 BCLL patients and compared it to several clinical and prognostic parameters including clinical stages and TTM scoring system. A good correlation was found among a) sCD23 and age (r = &#61485; .25, p = 0.028), TTM size (r = .53, p < 0.001), lymphocyte count (r = .42, p < 0.001), lymph node size (r = .43, p < 0.001), spleen size (r = .30, p = 0.008), B2MG (r = .41, p < 0.001), Rai stages (r = .23, p = 0.043) ; b) B2MG and TTM size (r = .60, p < 0.001), lymph node size (r = .49, p < 0.001), spleen size (r = .65, p < 0.001), sCD23, Rai stages (r = .41, p < 0.001), Binet stages (r = .41, p < 0.001), while c) LDH failed to correlate with any other parameter at a significant level. However, multivariate analyses disclosed a distinction between sCD23 and B2MG. While sCD23 correlated with tumor burden in peripheral blood, lymph node, and to a lesser extent spleen compartments, serum levels of B2MG were not associated at a significant level with tumor burden in peripheral blood, but were strongly associated with the burden in spleen and lymph node compartments. Multiple stepwise regression with backward selection model supported the difference, with sCD23 associated only with TTM size (p = 0.018) and B2MG with spleen (p < 0.001). Factor analysis disclosed two factors, of which one was defined by high and significant correlation with sCD23, TTM size and lymphocyte count, and the other by high and significant correlation with B2MG, spleen, distribution and Rai and Binet stages. We conclude that both sCD23 and B2MG are good parameters for estimation of total tumor burden in CLL. However, they do not measure same tumor attributes. Their simultaneous use may be clinically more relevant. Since they show different sensitivity to distribution pattern of neoplastic cells in CLL syndrome, further studies including the co-expression with various adhesion molecules are warranted.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA